The interleukin (IL)-17A inhibitor secukinumab (Cosentyx) was effective in preventing radiographic progression among patients with ankylosing spondylitis (AS) over two years, a phase III study known as MEASURE-1 found. Until now, drugs used to manage ankylosing spondylitis have not consistently shown that they halt radiographic progression.

Click here for more.